Correlations between Serum Interleukins-2, -4 Levels and Some Biochemical Parameters in Iraqi Patients with Osteoporosis

Hind Sh. Ahmed* BSc, MSc, PhD

Abstract:

**Background:** Osteoporosis is a frequent disease that is manifested by reduced in mineral density and raised in fracture risk. Recent studies have indicated that osteoporosis is caused by composite connections among local and systemic regulators of bone cell function.

**Objective:** The purpose of this study was to investigate the relationship between interleukin-2, interleukin-4, and some biochemical markers in Iraqi patients with osteoporosis.

**Patients and Methods:** Forty five osteoporotic patients were incorporated in this study (30 women and 15 men). Serum fasting glucose, lipid profile, alkaline phosphatase activity, calcium, magnesium, interleukin-2, and interleukin-4 were measured in osteoporotic patients and compared them with the control group.

**Results:** There was a significant increase in serum fasting glucose, lipid profile except high density lipoprotein cholesterol, and serum alkaline phosphatase activity in osteoporotic patients as compared to the control, \( (P=0.001) \). Also, there was a significant increase in interleukin-2 and interleukin-4 in osteoporotic patients as compared to the control, \( (P=0.01) \). While there was a decrease in serum calcium and magnesium levels in osteoporotic patients as compared to the control. Also, there was a significant positive correlation between serum alkaline phosphatase activity with interleukin-2 and interleukin-4 levels in osteoporotic patients, \( (P=0.01) \).

**Conclusion:** Elevated levels of interleukin-2 and interleukin-4 along with some biochemical markers like; serum alkaline phosphatase in osteoporotic patients might include significant functions in the pathogenesis of osteoporosis.

**Keywords:** Osteoporosis, Interleukin-2, Interleukin-4.

---

**Introduction:**

Osteoporosis which is defined based on bone mineral density (BMD), is a skeletal disorder manifested by compromised bone strength. It is induced by an imbalance between osteoblastic bone formation and osteoclastic bone resorption (1). Osteoporosis is manifested by skeletal tenderness and inclination to fracture due to reduction of bone mass and descent of bone micro-architecture (2). It is metabolic bone disease preponderance in both men and women, especially when they become older (3). The incidence of this disease is mainly reliant on metabolic, genetic, nutrition, hormonal factors, and lifestyle (4). Obesity, dyslipidemia, hyperglycemia, and hypertension are factors connected with the incidence of osteoporosis (5).

Dyslipidemia is a risk factor for cardiac complications. Osteoporosis and cardiovascular disease (CVD) usually are viewed as split disease and parallel to extent in their pathophysiological mechanism (6). Osteoporotic subjects are at risk of CVD and stroke having higher atherogenic lipid levels than subjects without this problem (7).

Bone turnover markers (BTMs) have been shown to afford important information for the diagnosis and monitoring of metabolic bone disease. A numeral of BTMs can now be determined clinically, and are usually separated into two categories as markers of bone formation and markers of bone resorption. Bone formation markers reflect different phases of osteoblast in bone formation, for instance alkaline phosphatase (ALP) (8).

A sufficient intake of calcium (Ca\(^{2+}\)) is necessary to maximize and sustain bone density. A calcium poor diet is a major risk influence for osteoporosis, Ca\(^{2+}\) is mislaid from the bones owing to menopause and elderly (9). Calcium supplementation, particularly when combined with vitamin D, can lessen the rate of bone loss and fracture in subjects who are deficient in dietary Ca\(^{2+}\) such as the frail elderly (10).

The property of Mg\(^{2+}\) on obesity are vital to women’s health, as women are more expected to be obese than men (11). It is recommended that sphingolipids perform as regulators of extracellular Mg\(^{2+}\). In a low Mg\(^{2+}\) state, ceramide synthase is upregulated, adding to liberate of inflammatory cytokines (12). Phosphatidylcholine is implicated in lessening the lymphatic absorption of cholesterol and is a main constituent of high density lipoprotein (HDL), so furthering the significance of Mg\(^{2+}\) for maintaining cardiovascular health (13).

Recent studies have related osteoporosis to the immune system and osteoimmunology is now accepted as a new area of study (14). Though, osteoclasts, predisposed by pro-inflammatory cytokines and anti-osteoclastogenic cytokines, can repress such activity (15). Interleukin-2 (IL-2) has

---

*Dept. of Chemistry, College of Education for Pure Science (Ibn Al-Haytham)/ University of Baghdad Hind_shakir80@yahoo.com

J Fac Med Baghdad 275 Vol. 59, No.3, 2017
vital roles in key functions of the immune system, tolerance and immunity, mainly via its direct effects on T cells (16). Interleukin-4 (IL-4) is a 19-kDa pleiotropic type I cytokine. IL-4 an essential immune cytokine that regulates role of lymphocytes and macrophages, in addition to regulates osteoclastogenesis and bone resorption (17). Therefore, this study aimed to examine the relationship between IL-2, IL-4, and some biochemical markers in Iraqi patients with osteoporosis.

Patients and Methods:
The present work was carried out at Medical City Hospital during the period from May 2016 until the end of November 2016. Outpatients were cautiously segregated by taking into account patients' history of osteoporosis in the family and some other factors which may affect the bone turnover markers. A total of 45 numbers of patients (30 women and 15 men) were selected for the study while remaining 45 apparently healthy subjects (23 women and 22 men) were selected as controls. Fasting serum glucose (FSG), lipid profile including [total cholesterol (TC), triacylglycerol (TAG), high density lipoprotein cholesterol (HDL-C), and calculated low density lipoprotein cholesterol (LDL-C)], ALP activity, Ca\(^{2+}\), and Mg\(^{2+}\) were measured using a chemical analyzer in the medical laboratories. Cytokines levels were determined in sera via a sandwich immunoassay kit provided by Human IL-4 and IL-2, while there was a significant increase in body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP) in osteoporotic patients as compared to the controls, (P =0.01).

Table (2) shows the laboratory characteristics of the studied groups. There was a significant increase in FSG, TC, TAG, LDL-C, and ALP activity while a significant decrease in serum HDL-C was found in osteoporotic patients as compared to the controls, (P =0.001). Also, there was a significant increase in serum IL-2 and IL-4 in osteoporotic patients as compared to the controls, (P =0.01). There was a decrease in serum Ca\(^{2+}\) and Mg\(^{2+}\) levels in osteoporotic patients as compared to the controls, but it was not significant. Correlations coefficient between serum ALP activity and other variables in osteoporosis group in table (3) showed that there was a significant positive correlation between serum ALP activity with FSG, TC, TAG, and LDL-C, (P= 0.001). Also, there was a significant positive correlation between serum ALP activity with IL-2 and IL-4, (P= 0.01). While, there was a significant negative correlation between serum ALP activity and HDL-C, (P= 0.001).

Table 2: Laboratory characteristics of the studied groups.

| Parameter          | Osteoporosis (n= 45) | Control (n= 45) | P value |
|--------------------|----------------------|----------------|---------|
| FSG (mg/dl)        | 115.18 ± 0.46        | 84.70 ± 3.34   | 0.001   |
| TC (mg/dl)         | 210.70 ± 7.80        | 124.50 ± 2.80  | 0.001   |
| TAG (mg/dl)        | 185.90 ± 8.70        | 75.30 ± 4.90   | 0.001   |
| HDL-C (mg/dl)      | 40.30 ± 2.24         | 52.50 ± 1.60   | 0.001   |
| LDL-C (mg/dl)      | 133.20 ± 4.42        | 56.94 ± 0.22   | 0.001   |
| ALP (IU/l)         | 130.42 ± 6.50        | 65.32 ± 1.20   | 0.001   |
| Ca\(^{2+}\) (mg/dl)| 5.22 ± 0.50          | 10.39 ± 1.45   | 0.06    |
| Mg\(^{2+}\) (mg/dl)| 1.0 ± 0.30           | 2.02 ± 0.40    | 0.07    |
| IL-2 (ng/ml)       | 35.30 ± 1.50         | 28.60 ± 1.20   | 0.01    |
| IL-4 (ng/ml)       | 23.58 ± 1.93         | 15.50 ± 1.21   | 0.01    |
Correlations between Serum Interleukins-2,-4 Levels and Some Biochemical Parameters
in Iraqi Patients with Osteoporosis

Hind Sh. Ahmed

Table 3: Correlations between ALP activity and other variables in osteoporosis group

| Parameter | Correlation Coefficient (r) |
|-----------|----------------------------|
| ALP       |                           |
| FSG (mg/dl) | 0.80**                   |
| TC (mg/dl)  | 0.92**                   |
| TAG (mg/dl) | 0.98**                   |
| HDL-C (mg/dl) | -0.84**              |
| LDL-C (mg/dl) | 0.95**                  |
| Ca²⁺ (mg/dl) | -0.20                   |
| Mg²⁺ (mg/dl) | -0.15                   |
| IL-2 (ng/ml) | 0.75*                    |
| IL-4 (ng/ml) | 0.70*                    |

*P = 0.01, **P = 0.001

Discussion:

Osteoporosis is a developing main public health difficulty with influences on quality and quantity of life that pass medical, social, and economic lines (18). Lifestyle-associated metabolic disorders include disorders of glucose metabolism such as hyperglycemia, hypercholesterolemia, and dyslipidemia (19). Blood glucose level was higher in osteoporotic group than in the controls. Current lines of researches have demonstrated that high blood glucose foremost to impaired osteoblast-mediated bone formation, accelerated bone resorption, microstructural defect, and reduced bone quality (20). Two studies reported the risk of fractures related with lipid levels (21, 22). It has shown that elevated LDL-C and low levels of HDL-C are related with low bone mineral density (23). Management of dyslipidemia requires multidimensional approach like dietary alterations and integration of healthy activity was of central importance in the overall concern plane (24).

The BTMs have influenced the evaluation and treatment of osteoporosis. Elevated levels of bone turnover markers are related with 2-fold increased risk of osteoporotic fracture as well as suggestive to other metabolic bone diseases. The BTMs are significant in management of osteoporosis treatment and thus recognition of optimum treatment for an individual is of primary importance, which could be achieved by estimating bone metabolism (25). Alkaline phosphatase is one of the BTMs, used as a marker of bone metabolism for the management of patients with metabolic bone disease such as paget’s disease, hyperparathyroidism, metastatic bone disease, and osteoporosis, ALP might help to guide treatment choices for antiresorptive drugs (26) and also to determine an previous signal of response to treatment usefulness than bone density assessments (27). Many bone diseases affect a demineralization process and therefore many treatments are designed for inhibiting bone resorption. Measurement of a bone resorption marker is thus more pertinent to the assessment of improved bone loss with ailment (28).

In this study, a significant increase in ALP activity was found in osteoporotic patients compared to the controls which is in accordance with the study of Khan et al., (29). Calcium (Ca²⁺) is a key constituent of bone (30). In the elderly, particularly among women, Ca²⁺ losses from bone can result in osteoporosis, and it is connected with low levels of circulating vitamin D. There has been much research on dietary supplementation of vitamin D and Ca²⁺ and in the old people, with the goal of minimizing osteoporosis and its complications, such as improved risk of bone fractures (31). Magnesium is a key mineral used for over 300 enzyme functions in the body. It has several approved health claims including its involvement to the maintenance of normal bones. Most Mg²⁺ supplements are solitary sourced, which may not be well absorbed in the gut. A multi-sourced Mg²⁺ supplement is ideal as it will offer an equilibrium of high Mg²⁺ content and good bioavailability (32). Magnesium insufficiency is simply detected with biochemical indications like resistance to vitamin D, low serum Ca²⁺ and Mg²⁺ levels, or clinical symptoms like, muscle cramps, muscle twitching, irregular heartbeat, and elevated blood pressure. It has been postulated that Mg²⁺ is required to prevent osteoporosis in the overall population (33). In the present study, there was a decrease in serum Ca²⁺ and Mg²⁺ levels in osteoporotic patients as compared to the controls.

Visceral fat accumulation is related with higher levels of pro-inflammatory cytokines, which may up-regulate receptor activators of nuclear kappa B ligand, leading to increased bone resorption and therefore decreased BMD (34). Though the definite cytokines rise over time, the properties of cytokines are not completely stated. It was revealed that IL-2 has vital functions in the pathogenesis of osteoporosis (35). It have been postulated that IL-2 is a positive regulator which is able of stimulating osteoclastic bone resorption. IL-2 is one of the major causes of decreased bone mineral density and bone formation (36). Interleukin-4 has been shown to act directly on osteoclast precursors and reduce osteoclastogenesis.

Interleukin-4 induced intracellular Ca²⁺ changes, the method by which IL-4 acts on intracellular Ca²⁺ is until now to be determined. These consequences propose that IL-4 acts directly on mature osteoclasts and inhibit bone resorption throughout Ca²⁺ signaling probably by IL-4R-mediated mechanism. It is also reported that IL-4 prevents bone and cartilage damage in collagen-provoked arthritis (37). In the current study, there was a significant raise in serum IL-2 and IL-4 levels in osteoporotic patients as compared to the controls which is similar to the result of Wenxi et al., study (38).

Conclusions:

Elevated levels of IL-2 and IL-4 along with some biochemical markers like; serum ALP in osteoporotic patients might include significant functions in the pathogenesis of osteoporosis.
Correlations between Serum Interleukins-2,-4 Levels and Some Biochemical Parameters

Hind Sh. Ahmed

in Iraqi Patients with Osteoporosis

References:
1- Paiva KB and Granjeiro JM. Bone tissue remodeling and development: Focus on matrix metalloproteinase functions. Arch Biochem Biophys. 2014; 561C:74-87.
2- Sugimoto T, Sato M, Dehle FC, Brnabic AJ, Weston A, and Burge R. Lifestyle-related metabolic disorders, osteoporosis, and fracture risk in Asia: A systematic review. Value Health Reg, 2016; 9:49-56.
3- Mechanick JI, Camacho PM, Garber AJ, Garber JR, Pessah-Pollack R, Petak SM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Protocol for Standardized Production of Clinical Practice Guidelines, Algorithms, and Checklists-2014 Update and the AACE G4G Program. Endocr Pract. 2014; 20(7):692-702.
4- Hippisley-Cox J and Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: Prospective derivation and validation of Q Fracture Scores. BMJ. 2009; 339:b4229.
5- Muka T, Trajanoska K, Kieft-de Jong JC, Oei L, Uitterlinden AG, Hofman A, et al. The association between metabolic syndrome, bone mineral density, hip bone geometry and fracture risk: The Rotterdam Study. PLOS ONE. 2015; 10:e0129116.
6- Miller M. Dyslipidemia and cardiovascular risk: The importance of early prevention QJM monthly journal of the association of physicians 2009; 102(9): 657-667.
7- Makovey J, Macara M, Chen JS, Hayward CS, March L, and Sambrook PN. High osteoporotic fracture risk and CVD risk co-exist in postmenopausal women. Bone. 2013; 52(1):120-125.
8- Lee J and Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 2012; 32(2): 105-112.
9- Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporosis Int. 2014; 25(10):2359-2381.
10- Bolland M, Grey A, and Reid I. Calcium and cardiovascular risks. Aust Prescr 2013; 36(1):5-8.
11- Shay CM, Van Horn L, Stamle J, Dyer AR, et al. Food and nutrient intakes and their associations with lower BMI in middle-aged US adults: The International study of macro-micronutrients and blood pressure (INTERMAP). The American Journal of Clinical Nutrition. 2012; 96(3):483-491.
12- Altura BM, Shah NC, Zhang A, et al. Short-term magnesium deficiency up-regulates ceramide synthase in cardiovascular tissues and cells: Cross-talk among cytokines, Mg^{2+}, NF-kB, and de novo ceramide. The American Journal of Physiology-Heart and Circulatory Physiology. 2012; 302(1):H319-H332.
13- Altura BM, Shah NC, Shah GJ, et al. Short-term Mg deficiency up-regulates protein kinase C isoforms in cardiovascular tissues and cells; relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-Zeta: Hypothesis and review. International Journal of Clinical and Experimental Medicine. 2014; 7(1): 1-21.
14- Feng W, Xia W, Ye Q, and Wu W. Osteoclastogenesis and osteoimmunology. Front Biosci (Landmark Ed). 2014; 1(19):758-767.
15- Zapan J, Komadina R, and Marc J. The relationship between osteoclastogenic and anti osteoclastogenic pro-inflammatory cytokines differs in human osteoprototic and osteoarthritis bone tissues. J Biomed Sci. 2012; 1(19):28.
16- Liao W, Lin XJ, and Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Current Opinion in Immunology. 2011; 23(5):598-604.
17- Riancho JA, Zarraheita MT, and Gonzalez-Macias J. Interleukin-4 modulates osteoclast differentiation and inhibits the formation of resorption pits. 1993; 196(2):678-685.
18- Camacho PM, Petak SM, Binkley N, Clarke BL, and Harris ST. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2016; 22(4):1-41.
19- Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28(4):629-636.
20- Al-Daghrim NY, Yakout S, Aljohani N, Al-Saleh Y, Al-Attas OS, McTernan PG, et al. Changes in serum cytokines and vitamin D in Saudi postmenopausal women with osteoporosis. Int J Clin Exp Med 2017; 10(1):1179-1185.
21- Tatsuno I, Terano T, Nakamura M, et al. Lifestyle and osteoporosis in middle-aged and elderly women: Chiba bone survey. Endocr J. 2013; 60(5):643-650.
22- Yamaguchi T, Sugimoto T, Yano S, et al. Plasma lipids and osteoporosis in postmenopausal women. Endocr J 2002; 49(2):211-217.
23- McFarlane SI, Muntyapppa R, Shin JJ, Bahityar G, and Sowers J.R. Osteoporosis and cardiovascular diseases: brittle bones and boned arteries, is there a link? Endocrine. 2004; 23(1):1-10.
24- Ito MK. Dyslipidemia: a management using optimal lipid lowering therapy. The Annals of Pharmacotherapy. 2012; 46(10):1368-1381.
25- Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab. 2011; 89(13):3627-3637.
26- Rosalki SB and Foo AY. Lectin affinity electrophoresis of alkaline phosphatase for the differentiation of bone hepatobiliary disease. Electrophoresis 1987: 10(8-9): 604-611.
27- Woitge H, Seibol MJ, and Ziegler R. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorders
Correlations between Serum Interleukins-2,-4 Levels and Some Biochemical Parameters

Hind Sh. Ahmed
in Iraqi Patients with Osteoporosis

or metabolic bone disease. Clin Chem. 1996; 42:1796-1804.
28- Van Straalen JP, Sanders E, Prummel MF, and Sanders GT. Bone alkaline phosphatase as indicator of bone formation. Clin Chim Acta. 1991; 201(1-2):27-33.
29- Khan A, Hanif M, Ahmed A, Habib S, and Kamal S. Correlation between bone turnover markers and bisphosphonates treatment in postmenopausal osteoporosis. Int.j.pathol.2016; 14(3):102-108.
30- Beto JA. The role of calcium in human aging. Clin. Nutr. Res. 2015; 4(1):1-8.
31- Machado MC, Bruce-Mensah A, Whitmire M, and Rizvi AA. Hypercalcemia associated with calcium supplement use: Prevalence and characteristics in hospitalised patients. J. Clin. Med. 2015; 4(3):414-424.
32- Strotman P, Lack W, Bernstein M, Stover M, and Summers H. Evaluation of common fractures of the hip in the elderly. Current Geriatrics Reports. 2016; 5(1): 38-43.
33- Jackson RD, Bassford T, Cauley J, et al. The impact of magnesium intake on fractures: results from the women’s health initiative observational study (WHI-OS). ASBMR. 2003
34- Campos RMS, de Piano A, da Silva PL, Carnier J, Sanches PL, Corgosinho FC, et al. The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: effects of long-term interdisciplinary therapy. Endocrine 2012; 42(1):146-156.
35- Gur A, Denli A, Cevik R, Nas K, Karakoc M, and Sarac AJ. The effects of alendronate and calcitonin on cytokines in postmenopausal osteoporosis. A 6-month randomized and controlled study. Yonsei Med J. 2003; 44:99-109.
36- Abdelmagid SM, Barbe MF, and Safadi FF. Role of inflammation in the aging bones. LifeSci. 2015; 123:25-34.
37- Mangashetti LS, Khapli SM, and Mohan R.W. IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-κB and Ca^{2+} signaling. J Immunol 2005; 175(2):917-925.
38- Wenxi D, Shufang D, Xiaoling Y, and Liming Y. Panax notoginseng saponins suppress radiation-induced osteoporosis by regulating bone formation and resorption. Phytomedicine. 2015; 22(9):813-819.